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The Dermatology Life Quality Index, the first dermatology-
specific health-related quality of life (HRQoL) questionnaire,
was published in 1994 (Finlay and Khan, 1994). There is
now 10 years experience with over 85 peer reviewed
research articles and 52 published abstracts describing its
use: there are also many current studies worldwide using
the DLQI as an outcome measure. The aim of this review
article is to provide detailed information about where to find
any published aspect of the DLQI so that the reader can
readily decide whether the DLQI may be appropriate for
their use. The DLQI was designed to be simple and easy to
use in a busy clinical setting: wide experience of its use has
confirmed the appropriateness of this concept.
There are other well-validated similar outcome mea-
sures: these include Skindex (Chren et al, 1996), Dermatol-
ogy Quality of Life Scales (Morgan et al, 1997), and
Dermatology-specific Quality of Life Instrument (Anderson
and Rajagopalan, 1997). de Korte et al (2002) and de Tiedra
et al (1998) have compared the characteristics of various
HRQoL outcome measures used in dermatology. Many
concepts to be considered when choosing quality of life
measures in dermatology have been reviewed (Finlay,
1997).
DLQI Description
The DLQI consists of 10 questions concerning symptoms
and feelings, daily activities, leisure, work, and school,
personal relationships and treatment.
Each question is answered by a tick box: ‘‘not at all’’, ‘‘a
little’’, ‘‘a lot’’ or ‘‘very much’’. Each question is scored from
0 to 3 and the scores summed, giving a range from 0 (no
impairment of life quality) to 30 (maximum impairment). All
questions relate ‘‘to the last week’’. The DLQI was designed
to be used in adults over the age of 18 years.
Methods
The articles and abstracts in which the DLQI has been used
have been identified by searching Medline, PubMed, and
the Science Citation Index, and by a constant review of the
major dermatology literature over the last 10 years up to
December 2003.
Validation
Comparison with normal population The DLQI questions
were designed to be specific to skin disease, with all 10
questions mentioning skin. There is a very high specificity of
the DLQI when compared with the normal population,
confirmed in seven studies (Table I). The mean DLQI scores
(maximum 30) in normal populations ranged from 0 to 0.5.
Repeatability The ability of a questionnaire to give a
closely similar score if repeated after a short time in a
patient with stable disease is an important characteristic to
be fulfilled. This has been confirmed for the DLQI in four
studies (Table II).
Internal consistency Internal consistency for the DLQI
has been examined in five studies (Table III). These have
demonstrated Cronbach’s a scores ranging from 0.83 to
0.93. Rank correlation has also been measured. This test
determines the degree of consistency of responses be-
tween questions. The higher the rank correlation value the
higher the consistency.
Sensitivity to change For any outcome measure to be of
value in the assessment of intervention, the measure must
be sensitive to change. This has been confirmed for the
DLQI in 53 studies describing sensitivity to change in 11
diseases (Table IV), and interventions within seven different
health service research settings (Table V). It should be noted
that all the questions in the DLQI relate to ‘‘over the last
week’’. It is therefore not appropriate to administer the DLQI
to an individual at an interval of less than 1 week.
Validation with other HRQoL measures and other out-
come measures The DLQI has been used in parallel with
nine other dermatology specific measures (Table VI) and
with seven general health measures (Table VII). Other
general health measures that have been used in compar-
ison with the DLQI are willingness to pay (Lundberg et al,
1999) and total illness burden (Fivenson D et al, 2002). An
illustrated version of the DLQI (Loo et al, 2003) has been
evaluated, but it was not possible to demonstrate exact
equivalence to the text only version.
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Time for completion The mean time for completion of the
text only version of the DLQI is 124 s (Loo et al, 2003). The
mean time taken for a cartoon and text version was reduced
to 88 s. Hahn et al (2001) recorded that patients took
between 1 and 3 min to complete the DLQI.
Meaning of scores There has been very little published
concerning the absolute meaning of dermatology HRQoL
scores and the nature of the minimally important score
change. The minimally important score change is the score
change that is considered by a patient to be clinically
relevant in contrast to a score change which might be
statistically significant. Preliminary work concerning this has
been carried out for the DLQI1,2.
Diseases Where DLQI Used
The DLQI has been used in over 36 different skin conditions
(Table VIII). It has been most widely used in psoriasis (30
studies), atopic eczema (21 studies), acne (10 studies),
vitiligo (five studies) and chronic urticaria (four studies).
Health Service Research
The use of HRQoL measures is particularly appropriate as
an outcome measure in health service research, as the data
generated give insight into the ‘‘consumer’s’’ viewpoint. The
DLQI can be rapidly and accurately completed by patients
unaided and be administered by post with minimal instruc-
tions, characteristics of benefit in large-scale studies.
Fourteen studies are summarized in Table V.
Countries In Which DLQI Used
Although the DLQI was created in the United Kingdom, it
has been used in at least 20 countries (Table IX) and it
Table I. DLQI used in the normal population
Number of
normal population
Number of
patients Disease
Mean DLQI
normal population Mean DLQI patients References
100 237 Eczema 0.3 4.2 Badia et al (1999)
Psoriasis 4.5
100 200 All 0.5 7.2 Finlay and Khan (1994)
14 19 Operating room nurses 0 3.3 Hachem et al (2002)
22 32 Atopic dermatitis – – Linnet and Jemec (1999)
100 300 Outpatients 0.4 7.9 Zachariae et al (2000)
Inpatients 12.9
100 340 All 0.5 9.6 a
28 48 Psoriasis 0.1 12.5 a
– – – – – a
aEtemesi BA: Quality of life in Tanzanian adults with chronic skin disease. Ann Dermatol Venereol 129:1S253, 2002 (abstract).
bUrbanowski S, Kosmowski W, Quality of life, psychological condition, depression and alexithymia in patients with psoriasis vulgaris. Ann Dermatol
Venereol 129:1S798, 2002 (abstract).
cFinlay AY, Myon E, Taieb C: Immoderate exposure to the sun: short-term impact on quality of life. JEADV 17:62, 2003 (abstract).
Table II. Test-retest repeatability of the DLQI
Number of
patients Statistical test References
94 Interclass correlation
coefficient
Badia et al (1999)
Eczema 0.77 (95% CI)
Psoriasis 0.90 (95% CI)
53 Spearman’s rank correlation Finlay and Khan
(1994)
Overall r¼0.99
po0.0001
Individual questions
r¼ 0.95–0.98
po0.001
38 Spearman’s rank correlation
coefficient 0.97
Jobanputra and
Bachmann (2000)
po0.0001
26 Reliability Zachariae et al (2000)
General 0.93
po0.01
Individual items 2–10
Range 0.62–0.88
po0.001
Item 1
0.32 (not significant)
1 Khilji FA, Gonzalez M, Finlay AY: Clinical meaning of change in
Dermatology Life Quality Index scores. Br J Dermatol 147(Suppl.
62):50, 2002 (abstract).
2 Hongbo Y, Harrison MA, Salek MS, Finlay AY: Assessing the
meaningfulness of Dermatology Life Quality Index (DLQI) scores.
JEADV 17(Suppl. 3):113, 2003 (abstract).
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Table III. Internal consistency of the DLQI
Number of patients Statistical test References
237 Cronbach’s alpha 0.83 Badia et al (1999)
200 Rank correlation range 0.23–0.70 Finlay and Khan (1994)
p¼0.002
607 Cronbach’s alpha 0.83 Jobanputra and Bachmann (2000)
Inter-item rank correlation coefficient range 0.04–0.54
230 Cronbach’s alpha 0.9 Mork et al (2002a, b)
Paired correlation between items range 0.20–0.76
po0.01
300 Cronbach’s alpha 0.88 Zachariae et al (2000)
Table IV. Treatments in which the DLQI has been used
Condition and treatment
No. of
studies
No. of
patients
evaluated
post-treatment
Mean DLQI
References
Additional
references
where DLQI score
not statedBefore After
Acne––adapalene 2 877 12.9 1.3 Grosshans et al (1998)a
Blue light phototherapy 1 21 6.1 4 b
Isotretinoin 2 104 6.7 2.8 Newton et al (1997);
Grosshans et al (1998)
Amyotrophic lateral
sclerosis––botox
1 5 – – Giess et al (2000)
BCC––surgery 1 37 5.3 1.3 Blackford et al (1996)
Bullous pemphigoid––treatment 1 153 6 2.1 Rzany et al (2000)
Chronic urticaria––fexofenadine 1 57 11.6 10.3 Thompson et al (2000)
Cosmetic camouflage 3 156 9.1 5.7 Holme et al (2002);
Boehncke et al (2002)
c
Eczema––autologous
blood therapy
1 15 8.4 4.1 Pittler et al (2003)
Cyclosporin 2 137 15.7 6.3 Czech et al (2000)d
Pimecrolimus 2 353 – – Reilly et al (2003)e
Psychotropic medicines 2 163 21.3 6.9 f,g
Tacrolimus 1 985 – – Drake et al (2001)
Topical steroids 1 114 4.4 1.6 Badia et al (1999)
UVB 1 12 10.8 3.6 Piletta et al (1996)
Hirsutism––ruby laser 1 15 12.8 7 Loo and Lanigan (2002)
Hydrotherapy 1 200 10.2 5.7 h
Hyperhidrosis––botox 1 94 10.3 8.8 Swartling et al (2001) Campanati et al (2003)
Endoscopic transthoracic
sympathectomy
1 33 – – i
Lymphoedema––skin hygiene 1 11 10.9 4.1 McPherson (2003)
Psoriasis––Alfacept 6 317 11.3 6.9 Finlay et al (2003) Ellis et al (2003)j,k,l,m,n,o
Clobetasol proprionate foam 1 16 – – Bergstrom et al (2003)
Cyclosporin 4 388 10.9 1.3 Touw et al (2001);
Ho et al (2001)p,q
DAB389IL-2 1 29 10.8 5.9 Bagel et al (1998)
Efalizumab 4 1008 12 6.9 Gordon et al (2003);
Shikiar et al (2003)
r
Etanercept 1 57 14 – Gottlieb et al (2003) s,t
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is currently being used in several others. The concepts
described in the 10 questions are very simple and ask about
very basic human concerns. The questions have conse-
quently been found to be appropriate across many different
cultures. One should not, however, assume that the
questions are necessarily universally appropriate: for
example, the question about sexual difficulties may not be
acceptable in some cultures.
Languages
The DLQI has been translated into at least 21 different
languages (Table X). Other translation processes are currently
underway. The majority of these translations are fully validated
with appropriate independent forward and back translation,
appropriate correction and further forward and backward
translation. This is to ensure that the scores gained from the
use of the DLQI in different languages can be compared.
Children’s Version
There is a children’s version of the DLQI (Lewis-Jones and
Finlay, 1995), the Children’s Dermatology Life Quality Index
(CDLQI). A text and cartoon version of this has been
described (Holme et al, 2003): the cartoon version is more
quickly completed by children than the text-only version
and is preferred by them.
Discussion
There are several reasons for trying to measure the impact
of skin disease on patients’ lives. HRQoL measures provide
Table IV. Continued
Condition and treatment
No. of
studies
No. of
patients
evaluated
post-treatment
Mean DLQI
References
Additional
references
where DLQI score
not statedBefore After
Heliotherapy 1 87 – – Amir et al (2001)
Hu1124Ab 1 52 11.9 5.7 u
Infliximab 1 7 – – Chan and Gebauer (2003)
Supervised climatotherapy 1 459 1.5 0.9 Mork et al (2002 b)
Topical steroids 1 123 4.8 2.7 Badia et al (1999)
Vitiligo––pigmentary clinic 1 141 10.7 7.1 Parsad (2003)
Cognitive behavioral therapy 1 21 15 5 Papadopoulos, Bor R and
Legge et al (1999)
Cosmetic camouflage 1 62 7.3 5.9 v
aSamgin MA, Monakhov SA. Adapalene gel 0.1% in the treatment of acne in Moscow. JEADV 17(Suppl. 3):166, 2003.
bAmmad S, Edwards C, Gonzalez M, Mills CM. The effect of blue light phototherapy on mild to moderate acne. Brit J Dermatol 147(Suppl 62):95, 2002
(abstract).
cFeldman SR, McMichael A, Balkrishnan R, Rapp SR, Crambes O, Abella ML, Bouloc A. The effect of corrective cosmetics on quality of life of patients
with facial disfigurements. JEADV 17(Suppl. 3):202, 2003.
dKochergin, NG, Burova EP. Life quality assessment in psoriasis and atopic dermatitis. JEADV 15(Suppl. 2):186, 2001 (abstract).
eMeurer M, Folster-Holst R, Brautigam M. Primecrolimus (SDZ ASM 981) cream improves disease control and quality of life in the long-term
management of atopic dermatitis in adults. Ann Dermatol Venereol 129:1S47, 2002 (abstract).
fKochergin, NG, Burova EP. Life quality assessment in psoriasis and atopic dermatitis. JEADV 15(Suppl. 2):186, 2001 (abstract).
gLvov AN, Ivanov OL, Ostrishko VV, et al. Psychoneurological parameters and quality of life in patients with severe forms of atopic dermatitis. JEADV
15(Suppl. 2):276, 2001 (abstract).
hSegard C, Verriere F, Nocera T, Myon E, Taieb C. Impact of hydrotherapy care on the quality of life of patients’ suffering from skin disease. Qual Life
Res 12:777, 2003.
iNicolaou M, Swan MC, Paes T. Endoscopic transthoracic sympathectomy: the effect on the quality of life of patients with facial, palmar and axillary
hyperhidrosis and facial blushing. JEADV 16(Suppl. 1):298, 2002 (abstract).
jChristophers E, Bourcier M, Griffiths C, et al. Study design and demographics of a randomised, double-blind, placebo-controlled phase 3 dose-
comparison study to evaluate weekly intramuscular administration of alefacept in chronic plaque psoriasis. JEADV 15(Suppl. 2):249, 2001 (abstract).
kGriffiths C, Langley R, Lebwohl M, et al. Alefacept improves psoriasis and quality of life: Results of an international trial. Ann Dermatol Venereol 129:1S280,
2002 (abstract).
lPapp K, Ellis C, Menter A, et al. Alefacept improves psoriasis and quality of life: Results of a multiple-course trial. Ann Dermatol Venereol 129:1S764, 2002
(abstract).
mGriffiths CEM, Humbert P, Koo J, Ortonne JP, Christophers E. Relationship between clinical response and quality of life in psoriasis patients treated with
alefacept. JEADV 16(Suppl. 1):292, 2002 (abstract).
nLangley R. An improvement of 50% or more in psoriasis area severity index (PASI) represents substantial improvement for patients treated with alefacept.
JEADV 17(Suppl. 3):139, 2003.
oChristopher E, Vanishnaw AK. A broad spectrum of patients with psoriasis benefit from alefacept therapy. JEADV 17(Suppl. 3):138, 2003.
pKochergin NG, Burova EP. Life quality assessment in psoriasis and atopic dermatitis. JEADV 15(Suppl. 2):186, 2001 (abstract).
qChaidemenos C, Avgoustinaki N, Karakatsanis G, Chatzistylianos M, Papakonstantinou M, Mourellou O. Effect of intermittent and continuous
cyclosporin therapy on the clinical and quality of life parameters of psoriasis. JEADV 17(Suppl. 3):381, 2003.
rSterry W. Psoriasis––impact on QoL––efalizumab positive outcomes. JEADV 17(Suppl. 3):439, 2003.
sCarey W, Gulliver WP. Efalizumab therapy improves and sustains health-related quality of life in patients with moderate to severe plaque psoriasis. JEADV
17(Suppl. 3):371, 2003.
tOuellet JP, Toth D, Gratton D. Efalizumab provides rapid onset of clinical benefit in patients with moderate to severe plaque psoriasis. JEADV 17(Suppl.
3):371, 2003.
uBissonnette R, Papp KA, Garovoy M, Walicke P, Watrous W. Hu 1124 improves dermatological-specific quality of life in subjects with moderate-severe
psoriasis. J Eur Acad Dermatol Venereol 14(Suppl. 1):255, 2000 (abstract).
vDierckxsen L, Ongenae K, van Geel N, Naeyaert J. Vitiligo and quality of life: impact of complexion corrector. JEADV 17(Suppl. 3):358, 2003.
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a patient orientated and relevant outcome measure in the
assessment of new therapies and in comparing different
ways of delivering health care. They provide a way of being
able to compare the impact of different skin diseases, and
compare the impact of skin diseases to diseases affecting
other organs. This information may be important to inform
decision taking concerning resource allocation in health
care systems and for political purposes in emphasizing the
TableV. Health Service Research using the DLQI
Type of Care Relevant disease
Number of
patients
DLQI
References
References
with insufﬁcient
dataBefore After
Day case treatment Psoriasis 33 10.5 7.2 Haynes (2000)
Inpatient treatment All 619 12.3 6.7 Kurwa and Finlay (1995); Haynes (2000);
Vensel et al (2000); Helbling et al (2002)
Ayyalaraju et al
(2003)
Nurse follow-up clinics Eczema psoriasis 381 10.7 7.6 Gradwell et al (2002)a
Outpatient consultation
with dermatologist
All 2487 4.6 3.1 bShum et al (2000) c
Patch testing Eczema 179 8.7 5.5 Thompson et al (2002); Woo et al (2003)
Primary care All 341 7.4 – Harlow et al (2000)
Primary care dermatology
liason nurses
Psoriasis eczema 35 6.1 4.6 Kernick et al (2000)
Teledermatology
treament time
All
All
123
53
6.3
10.8
–
–
Williams et al (2001)
Jemer and Kynemund (2001)
aWong CSM, Sewell M, Yell J. Nurse practitioners compare favourably with doctors in the treatment of eczema and psoriasis. Brit J Dermatol
149(Suppl 64):4–5, 2003.
bFinlay AY, Coles EC, Lewis-Jones MS, et al. Quality of life improves after seeing a dermatologist. Brit J Dermatol 139(Suppl. 51):15, 1998 (abstract).
cBerger K, Kugland B, Khlken B, Augustin M. Cost of chronic plaque psoriasis in Germany: An analysis from the patients and payer perspectives. J Eur
Acad Dermatol Venereol 17(Suppl. 1):36, 2003 (abstract).
TableVI. Dermatology-speciﬁc HRQoL measures and other outcome measures used in parallel with the DLQI
Measure References Number of patients Correlation coefﬁcient p-value
Assessment of the Psychological and
Social Effects of Acne (APSEA)
a 163 r¼0.65
po0.001
Acne Quality of Life Scale (AQOLS) b 108 po0.05
Cardiff Acne Disability Index (CADI) a 163 r¼0.65
po0.001
Life Activity Impairment Score (LAIS) c 300 r¼0.86
p¼ 0.05
Psoriasis Disability Index (PDI) Nichol et al (1996) 644 r¼0.82
po0.001
Physician’s Disease Severity Harris et al (1996) 279 Darier’s disease
p¼ 0.41
Hailey–Hailey Disease
p¼ 0.08
Jayaprakasam et al (2002) 57 r¼0.56
PSORIQoL McKenna et al (2003) 130 r¼0.7
Psoriasis quality of life index (PQLI) d 50 r¼0.99
Psoriasis Quality of Life Questionnaire (PQOL) Koo et al (2002) 474 –
aClark SM, Goulden V, Finlay AY, Cunliffe WJ. The psychological and social aspect of acne: a comparison study using three acne disability
questionnaires. Brit J Dermatol 137(Suppl. 40):41, 1997 (abstract).
bErtam I. Acne and quality of life: Is there a correlation between them in university students. Ann Dermatol Venereol 129:1S374, 2002 (abstract).
cAl-Awadi R, Dykes PJ, Gonzalez M, Finlay AY. Life activity impairment by skin disease. J Eur Acad Dermatol Venereol 14(Suppl. 1):54, 2000 (abstract).
dCallis KP, Carlin CS, Krueger CG. Correlation of National Psoriasis Foundation score components with quality of life measures in psoriasis. J Invest
Dermatol 121:0357, 2003.
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TableVII. General HRQoL measures used in parallel with the DLQI
Measure References Number of patients
r-value
p-value
Center for Epidemiological Studies
Depression Scale (CESD-10)
Williamson et al (2001) 70 r¼0.62
po0.0001
Euroqol EQ-5D Klassen et al (2000) 130
General health Questionnaire (GHQ-28) Kent and Al-Abache (1996) 627 r¼ 0.39
po0.001
Nottingham Health Profile (NHP) Badia et al (1999) 237 r¼0.32–0.12
Patient Generated Index (PGI) Herd et al (1997) 56 r¼0.4
po0.001
Ruta et al (1998) 65 –
Rosenberg’s self-esteem Mallon et al (1999) 111 r¼0.4
po0.001
Kent and Al-Abadie (1996) 622 r¼0.4
po0.001
Short Form Health Survey
Questionnaire (SF-36)
Nichol et al (1996) 644 p¼ 0.001
Mallon et al (1999) 111 r¼0.5
po0.001
Ruta et al (1998) 65 –
Lundberg et al (2000) 366 r¼0.27–0.41
Kiebert et al (2002) 237 r¼0.27–0.58
po0.05
Fivenson et al (2002) 107 r¼0.42–0.57
UK Sickness Impact Profile (UKSIP) Blackford et al (1996) 44 r¼ 0.6
po0.01
TableVIII. Diseases and conditions in which the DLQI has been used
Condition
Total
number from
all studies
DLQI
References
Other references
with insufﬁcient
data
Range of
means
Mean of
means
Median of
means
Acne 838 4.3–17.7 11.9 6.1 Finlay and Khan (1994);a
Newton et al (1997);
Grosshans et al (1998);
Harlow et al (2000)b,c,d
Poli et al (2001)e
Alopecia areata 11 – 6.2 – Jobanputra and Bachmann (2000)
Atopic eczema 1409 4.5–21.4 12.2 11 Finlay and Khan (1994);
Kurwa and Finlay (1995);
Finlay (1996);
Piletta et al (1996);
Herd et al (1997);
Badia et al (1999);
Lundberg et al (1999);
Shum et al (2000);
Czech et al (2000);
Harlow et al (2000);
Jobanputra and
Bachmann (2000)f,g,h,i
Linnet and Jemec (1999);
Kernick et al (2000);
Drake et al (2001);j
Gradwell et al (2002)
Basal cell
carcinoma
52 2–5.3 4.8 – Finlay and Khan (1994);
Blackford et al (1996)
Behcet’s disease 325 – 5.7 – Blackford et al (1997)
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Table VIII. Continued
Condition
Total
number from
all studies
DLQI
References
Other references
with insufﬁcient
data
Range of
means
Mean of
means
Median of
means
Bullous
pemphigoid
25 – 6 – Rzany et al (2000)
Chronic urticaria 518 3.9–10.9 9.9 – Poon et al (1999);
Harlow et al (2000);
Jobanputra and
Bachmann (2000);
Thompson et al (2000)
Darier’s disease 135 – 5.9 – Harris et al (1996)
Discoid lupus
erythematosus
7 – 5 – Jobanputra and
Bachmann (2000)
Dystrophic
epidermolysis
bullosa
32 – 7.5 – Horn and Tidman (2002)
Epidermolysis
bullosa simplex
57 – 10.7 – Horn and Tidman (2002)
Hailey-Hailey
disease
66 – 6.1 – Harris et al (1996)
Hair loss 70 – 8.3 – Williamson et al (2001)
Hidradenitis
suppurativa
114 – 8.9 – Von der Werth and Jemec (2001)
Hirsutism 15 – 12.8 – Loo and Lanigan (2002)
Immoderate sun
exposure
– – – k
Latex allergy 36 – 11 – l
Leg ulcers 19 5.5–7 6.9 – Harlow et al (2000)
Lichen planus 5 – 5.8 – Harlow et al (2000)
Lymphoedema 68 – 10.9 – Boehncke et al (2002)m
Melasma 110 3.5–11.5 10.9 – Jobanputra and
Bachmann (2000);
Balkrishnan et al (2003)
Moles 17 1–2.7 2 – Finlay and Khan (1994);
Harlow et al (2000)
Nodular prurigo 6 – 8.7 – Jobanputra and
Bachmann (2000)
Occuptional
contact dermatitis
90 6.6–10.8 7.5 Jobanputra and
Bachmann (2000);
Hutchings et al (2001)
Primary focal
hyperhidrosis
58 – 10.3 – Swartling et al (2001) Campanati et al (2003)
Pityriasis rosea 7 – 6.6 – Harlow et al (2000)
Pruritus 15 10–10.5 10.3 – Finlay and Khan (1994);
Harlow et al (2000)
Psoriasis 2468 1.7–18.2 8.8 11.9 Finlay and Khan (1994);
Kurwa and Finlay (1995);
Nichol et al (1996);n
Bagel et al (1998);
Badia et al (1999);
Lundberg et al (1999);o
Harlow et al (2000);
Haynes (2000);
Vensel et al (2000);
Jobanputra and
Bachmann (2000);
Ho et al (2001);
Ruta et al (1998);u,v
Amir et al (2001) w,x
Ellis et al (2003),y
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Table VIII. Continued
Condition
Total
number from
all studies
DLQI
References
Other references
with insufﬁcient
data
Range of
means
Mean of
means
Median of
means
Touw et al (2002); a,p,q,r,s
Mork et al (2002a, b);
Hermansen et al (2002)t
Rosacea/
rhinophyma
38 6.3–7.8 6.7 – Harlow et al (2000); Hiltscher
et al (2001)
Scabies 7 – 8.6 – Harlow et al (2000)
Seborrhoeic
dermatitis
50 – 5.9 – Harlow et al (2000) z
Seborrhoeic warts 5 – 1.8 – Finlay and Khan (1994)
Sialorrhoea in
amyotrophic
lateral sclerosis
5 – – – Giess et al (2000)
Solar keratosis 5 – 3.4 – Finlay and Khan (1994)
Tinea 10 – 5.5 – Jobanputra and
Bachmann (2000)
Vitiligo 856 4.8–15 5.6 – Kent and Al-Abadie (1996);
Papadopoulos et al (1999);aa
Parsad et al (2003);ab
Warts 24 3.8–6.7 4.7 3.8 Finlay and Khan (1994);
Harlow et al (2000);
Jobanputra and
Bachmann (2000)
aClark SM, Goulden V, Finlay AY, Cunliffe WJ. The psychological and social aspect of acne: a comparison study using three acne disability
questionnaires. Brit J Dermatol 137(Suppl. 40):41, 1997 (abstract).
bZaghloul SS, Cunliffe WJ, Goodfield MJD. Compliance in acne is highly correlated to psychological well-being and self presentation. Brit J Dermatol
147(Suppl. 62):43, 2002 (abstract).
cAmmad S, Edwards C, Gonzalez M, Mills CM. The effect of blue light phototherapy on mild to moderate acne. Brit J Dermatol 147(Suppl. 62):95, 2002
(abstract).
dKochergin NG, Samgin MA, Monakhow SA. Acne, adapalene and quality of life. JEADV 16(Suppl. 1):116, 2002 (abstract).
eErtam I. Acne and quality of life: Is there a correlation between them in university students. Ann Dermatol Venereol 129:1S374, 2002 (abstract).
fKochergin, NG, Burova E P. Life quality assessment in psoriasis and atopic dermatitis. JEADV 15(Suppl. 2):186, 2001 (abstract).
gLvov AN, Ivanov OL, et al. Psychoneurological parameters and quality of life in patients with severe forms of atopic dermatitis. JEADV 15(Suppl.
2):276, 2001 (abstract).
hTaieb C, Nocera T, Verriere F, Myon E. Psoriasis and atopic dermatitis: cross-description of patients’ quality of life. JEADV 17:38, 2003 (abstract).
iHolm EA, Jemec GBE. Why is assessment of health-related quality of life so important? JEADV 17(Suppl. 3):304, 2003.
jMeurer M, Folster-Holst R, Brautigam M. Primecrolimus (SDZ ASM 981) cream improves disease control and quality of life in the long-term
management of atopic dermatitis in adults. Ann Dermatol Venereol 129:1S47, 2002 (abstract).
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sCalikoglu E, Oztas P, Cetin P. The evaluation of psychiatric tests in seborrhoeic dermatitis patients. JEADV 17(Suppl. 3):159, 2003.
tCallis KP, Carlin CS, Krueger CG. Correlation of National Psoriasis Foundation score components with quality of life measures in psoriasis. J Invest
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importance of skin disease. The DLQI has been used for
all of these purposes. In the direct clinical consultation
allowing patients to express the issues in their lives caused
by their skin disease can enhance the quality of care
provided. HRQoL measures may in the future be helpful in
informing clinical decision taking where consideration is
being given to using expensive or potentially harmful
therapies.
As the planning of health care is becoming increasingly
patient-orientated, quality of life measurements will con-
tinue to be a vital means of assessing how individual
patients are affected by skin conditions (Tulloch and
Ormerod, 2003). There are a variety of HRQoL measures
that can be used in dermatology, including disease-specific,
dermatology-specific and general health measures (Finlay,
1997). This survey of published information relating to the
DLQI is not intended to indicate whether or not the DLQI
should be used in individual circumstances, but rather to
make it easier for potential users to access information
about the various strengths and weaknesses of this
instrument. It is important that validity of outcome measures
should be demonstrated and that data related to this be
easily accessible. In addition to the published experience
reviewed in this survey, the DLQI is currently being used in
many studies worldwide and this survey should be
informative to current users.
Perhaps the biggest challenge to the development of our
understanding of HRQoL measures is for research to be
focused on giving HRQoL scores some direct meaning for
clinicians. Before the DLQI is likely to be used widely in the
direct clinical setting however, it will be necessary to know
how score ranges of the DLQI relate to patients’ overall view
of their HRQoL; an initial banding proposal2 is likely to be
altered based on a much larger study. The size of change in
scores that are of relevance to patients will also have to be
more clearly established. As the DLQI is a simple measure
which is accurately and rapidly completed by patients with
no supervision, it does have the potential, as originally
intended (Finlay and Khan, 1994), to be of direct help to
clinicians.
Further Information
Further information about the DLQI is available from
FinlayAY@cf.ac.uk and at www.ukdermatology.co.uk The
DLQI is copyright: Library of Congress United States
copyright office registration number TXu 608 406, date of
registration December 6, 1993. Permission is usually given
for the use of the DLQI for academic purposes or by
individual clinicians without charge. Under some circum-
stances a small charge is made.
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